Enterome Extends Its Microbiome Platform
This article was originally published in Start Up
The French firm has partners for its diagnostics, wants to spin out a "stool banking" company, and might follow other microbiome start-ups into drug discovery to explore the connections between our bugs and our immune system.
You may also be interested in...
Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
Intercept Stock Price Skyrockets On Continuing Stream Of Good Data For OCA Candidates
Early stop due to efficacy of NIH Phase II trial in non-alcoholic steatohepatitis could mean quick pathway to approval for compound in this unmet medical need. A growing liver disease, Intercept believes NASH is an under-recognized opportunity, which could outstrip HCV and cirrhosis as a cause of liver transplantation.
J&J’s Boston “Deal-Making Machine” Backs Two Start-Ups
The third of Johnson & Johnson’s four Innovation Centers, designed to give the behemoth company access and proximity to early-stage scientific innovation, opened June 27 in Boston. Concurrently, the company backed two VC-funded young start-ups , as well as a hospital alliance and a laboratory initiative.